{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T08:59:16Z","timestamp":1793350756586,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 113-2320-B-039-063"],"award-info":[{"award-number":["NSTC 113-2320-B-039-063"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 114-2320-B-039-066"],"award-info":[{"award-number":["NSTC 114-2320-B-039-066"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.intimp.2026.117115","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T03:45:50Z","timestamp":1784000750000},"page":"117115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Pemetrexed potentiates \u03b3\u03b4 T cell-based immunotherapy in NSCLC through ATM-STING-NF-\u03baB-mediated induction of NKG2D ligands"],"prefix":"10.1016","volume":"186","author":[{"given":"Meng-Yu","family":"Hung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hsuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Der-Yang","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Chih","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Ming","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Yuan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Wen","family":"Kan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin Chih-Yang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Chih","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2026.117115_bb0005","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41392-023-01653-8","article-title":"Gammadelta T cells: origin and fate, subsets, diseases and immunotherapy","volume":"8","author":"Hu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"12","key":"10.1016\/j.intimp.2026.117115_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14123005","article-title":"Human gammadelta T cell subsets and their clinical applications for cancer immunotherapy","volume":"14","author":"Lee","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2026.117115_bb0015","article-title":"A close look at current \u03b3\u03b4 T-cell immunotherapy","volume":"14","author":"Ma","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117115_bb0020","first-page":"23","article-title":"\u0393\u03b4 T cell therapy for the treatment of non-small cell lung cancer","volume":"3","author":"Kakimi","year":"2014","journal-title":"Transl Lung Cancer Res"},{"issue":"3","key":"10.1016\/j.intimp.2026.117115_bb0025","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1284723","article-title":"Assessment of tumor-infiltrating TCRV\u03b39V\u03b42 \u03b3\u03b4 lymphocyte abundance by deconvolution of human cancers microarrays","volume":"6","author":"Tosolini","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.intimp.2026.117115_bb0030","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3389\/fonc.2018.00508","article-title":"Vgamma9Vdelta2 T cells as strategic weapons to improve the potency of immune checkpoint blockade and immune interventions in human myeloma","volume":"8","author":"Castella","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2026.117115_bb0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.02186","article-title":"Pro-tumor gammadelta T cells in human cancer: polarization, mechanisms of action, and implications for therapy","volume":"11","author":"Chabab","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117115_bb0040","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12943-023-01722-0","article-title":"Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment","volume":"22","author":"Gao","year":"2023","journal-title":"Mol. Cancer"},{"issue":"7980","key":"10.1016\/j.intimp.2026.117115_bb0045","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41586-023-06525-3","article-title":"Phosphoantigens glue butyrophilin 3A1 and 2A1 to activate Vgamma9Vdelta2 T cells","volume":"621","author":"Yuan","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2026.117115_bb0050","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3389\/fimmu.2015.00015","article-title":"Five layers of receptor Signaling in gammadelta T-cell differentiation and activation","volume":"6","author":"Ribeiro","year":"2015","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2026.117115_bb0055","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00262-016-1814-9","article-title":"MHC class I chain-related molecule a and B expression is upregulated by cisplatin and associated with good prognosis in patients with non-small cell lung cancer","volume":"65","author":"Okita","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"issue":"10","key":"10.1016\/j.intimp.2026.117115_bb0060","first-page":"2064","article-title":"Role of NKG2D and its ligands in cancer immunotherapy","volume":"9","author":"Liu","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.intimp.2026.117115_bb0065","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3389\/fimmu.2019.00661","article-title":"NKG2D\/NKG2-ligand pathway offers new opportunities in Cancer treatment","volume":"10","author":"Frazao","year":"2019","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2026.117115_bb0070","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/emm.2006.56","article-title":"Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation","volume":"38","author":"Kim","year":"2006","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.intimp.2026.117115_bb0075","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3389\/fimmu.2019.00569","article-title":"Histone deacetylase inhibitor modulates NKG2D receptor expression and memory phenotype of human gamma\/Delta T cells upon interaction with tumor cells","volume":"10","author":"Bhat","year":"2019","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2026.117115_bb0080","doi-asserted-by":"crossref","first-page":"5954","DOI":"10.18632\/oncotarget.13979","article-title":"Low-dose bortezomib increases the expression of NKG2D and DNAM-1 ligands and enhances induced NK and \u03b3\u03b4 T cell-mediated lysis in multiple myeloma","volume":"8","author":"Niu","year":"2017","journal-title":"Oncotarget"},{"issue":"15","key":"10.1016\/j.intimp.2026.117115_bb0085","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1182\/blood-2008-08-173914","article-title":"ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype","volume":"113","author":"Soriani","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2026.117115_bb0090","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcyt.2020.09.010","article-title":"Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia","volume":"23","author":"Story","year":"2021","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.intimp.2026.117115_bb0095","doi-asserted-by":"crossref","first-page":"7656","DOI":"10.1038\/s41598-023-34827-z","article-title":"Combinatorial immunotherapy with gemcitabine and ex vivo-expanded NK cells induces anti-tumor effects in pancreatic cancer","volume":"13","author":"Koh","year":"2023","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.intimp.2026.117115_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139809","article-title":"Contrasting effects of the cytotoxic anticancer drug gemcitabine and the EGFR tyrosine kinase inhibitor gefitinib on NK cell-mediated cytotoxicity via regulation of NKG2D ligand in non-small-cell lung Cancer cells","volume":"10","author":"Okita","year":"2015","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.intimp.2026.117115_bb0105","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1424671","article-title":"Low dose gemcitabine increases the cytotoxicity of human V\u03b39V\u03b42 T cells in bladder cancer cells in vitro and in an orthotopic xenograft model","volume":"7","author":"Shimizu","year":"2018","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/j.intimp.2026.117115_bb0110","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/1758834016644155","article-title":"Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes","volume":"8","author":"Tomasini","year":"2016","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.intimp.2026.117115_bb0115","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.lungcan.2012.01.014","article-title":"Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer","volume":"77","author":"Mir","year":"2012","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2026.117115_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030666","article-title":"Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung Cancer","volume":"12","author":"Cavazzoni","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.intimp.2026.117115_bb0125","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001392","article-title":"Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy","volume":"8","author":"Lu","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.intimp.2026.117115_bb0130","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1111\/cas.14401","article-title":"Pemetrexed sensitizes human lung cancer cells to cytotoxic immune cells","volume":"111","author":"Okimoto","year":"2020","journal-title":"Cancer Sci."},{"issue":"7","key":"10.1016\/j.intimp.2026.117115_bb0135","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1111\/cas.15806","article-title":"Pemetrexed combined with dual immune checkpoint blockade enhances cytotoxic T lymphocytes against lung cancer","volume":"114","author":"Chen","year":"2023","journal-title":"Cancer Sci."},{"issue":"5","key":"10.1016\/j.intimp.2026.117115_bb0140","doi-asserted-by":"crossref","first-page":"C1313","DOI":"10.1152\/ajpcell.00494.2022","article-title":"RAGE potentiates EGFR signaling and interferes with the anticancer effect of gefitinib on NSCLC cells","volume":"325","author":"Liao","year":"2023","journal-title":"Am J Physiol-Cell Ph"},{"issue":"1","key":"10.1016\/j.intimp.2026.117115_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2020.100239","article-title":"Protocol for generation of lung adenocarcinoma organoids from clinical samples","volume":"2","author":"Li","year":"2021","journal-title":"STAR Protoc"},{"issue":"16","key":"10.1016\/j.intimp.2026.117115_bb0150","article-title":"Highly mimetic ex vivo lung-Cancer spheroid-based physiological model for clinical precision therapeutics","volume":"10","author":"Shie","year":"2023","journal-title":"Adv Sci (Weinh)"},{"issue":"3","key":"10.1016\/j.intimp.2026.117115_bb0155","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/jim-2021-002159","article-title":"Sequential administration of pemetrexed and cisplatin reprograms tumor immune microenvironment and potentiates PD-1\/PD-L1 treatment in a lung cancer model","volume":"70","author":"Yu","year":"2022","journal-title":"J. Invest. Med."},{"issue":"3","key":"10.1016\/j.intimp.2026.117115_bb0160","doi-asserted-by":"crossref","DOI":"10.1172\/JCI139333","article-title":"ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS\/STING activation","volume":"131","author":"Hu","year":"2021","journal-title":"J. Clin. Invest."},{"issue":"49","key":"10.1016\/j.intimp.2026.117115_bb0165","doi-asserted-by":"crossref","first-page":"7433","DOI":"10.1038\/s41388-019-0960-x","article-title":"Induction of NKG2D ligand expression on tumor cells by CD8(+) T-cell engagement-mediated activation of nuclear factor-kappa B and p300\/CBP-associated factor","volume":"38","author":"Hu","year":"2019","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.intimp.2026.117115_bb0170","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/onc.2016.259","article-title":"CBP\/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells","volume":"36","author":"Sauer","year":"2017","journal-title":"Oncogene"},{"issue":"63","key":"10.1016\/j.intimp.2026.117115_bb0175","doi-asserted-by":"crossref","first-page":"6805","DOI":"10.18632\/oncotarget.27308","article-title":"Clinicopathological relevance of tumor expression of NK group 2 member D ligands in resected non-small cell lung cancer","volume":"10","author":"Okita","year":"2019","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.intimp.2026.117115_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/cells9081757","article-title":"Engineering the bridge between innate and adaptive immunity for Cancer immunotherapy: focus on \u03b3\u03b4 T and NK cells","volume":"9","author":"Morandi","year":"2020","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.intimp.2026.117115_bb0185","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/s12935-023-03134-y","article-title":"The nexus of natural killer cells and melanoma tumor microenvironment: crosstalk, chemotherapeutic potential, and innovative NK cell-based therapeutic strategies","volume":"23","author":"Rahimi","year":"2023","journal-title":"Cancer Cell Int."},{"issue":"7","key":"10.1016\/j.intimp.2026.117115_bb0190","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41419-024-06911-3","article-title":"ATM inhibition enhance immunotherapy by activating STING signaling and augmenting MHC class I","volume":"15","author":"Li","year":"2024","journal-title":"Cell Death Dis."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926009616?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926009616?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:48:11Z","timestamp":1786322891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926009616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":38,"alternative-id":["S1567576926009616"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117115","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pemetrexed potentiates \u03b3\u03b4 T cell-based immunotherapy in NSCLC through ATM-STING-NF-\u03baB-mediated induction of NKG2D ligands","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117115","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117115"}}